Baxter Receives Positive Opinion for IVIG Therapy in Europe for Treatment of Multifocal Motor Neuropathy

Baxter International Inc.

announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion for extension of the therapeutic indications of KIOVIG to include a new indication for multifocal motor neuropathy, a severe, debilitating disorder requiring lifelong treatment. With adoption by the European Commission, Baxter will receive marketing authorization for KIOVIG MMN indication in all European Union Member States- the first centrally-licensed indication for an immunoglobulin preparation for MMN.